CellSearch System cleared for monitoring metastatic breast cancer
Metastatic breast cancer monitoring
Veridex, a Johnson & Johnson company, today announced that the U.S. Food and Drug Administration (FDA) has granted an expanded clearance for the CellSearch
Share this content.
If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.